Compare REPL & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | LAB |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.1M | 402.1M |
| IPO Year | 2018 | 2008 |
| Metric | REPL | LAB |
|---|---|---|
| Price | $10.68 | $1.21 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $5.67 | $1.35 |
| AVG Volume (30 Days) | ★ 8.0M | 1.9M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.25 | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | ★ N/A | $3.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $0.87 |
| 52 Week High | $13.24 | $1.72 |
| Indicator | REPL | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 79.44 | 72.03 |
| Support Level | $6.81 | $1.09 |
| Resistance Level | $10.67 | $1.40 |
| Average True Range (ATR) | 0.72 | 0.06 |
| MACD | 0.62 | 0.01 |
| Stochastic Oscillator | 89.91 | 98.00 |
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.